Immune Modulation Through Directed Th2 Polarization: Programming Naïve T Cells to Suppress Autoimmune Pathways in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motor neuron loss, neuroinflammation, and immune dysregulation. Increasing evidence demonstrates that a peripheral and central shift toward proinflammatory Th1 and Th17 immune responses correlate with disease severity and progression. In contrast, T helper type-2 (Th2)–associated immune responses exert neuroprotective and anti-inflammatory effects through cytokine-mediated suppression of pathogenic autoimmunity and modulation of microglial activity. This review positions immune modulation as a programmable therapeutic strategy, in which naïve CD4⁺ T cells (Th0) are actively biased toward a Th2 phenotype through cytokine conditioning and controlled induction of atopic immune signaling. Forced atopy establishes a Type 2–dominant cytokine microenvironment rich in IL-4, IL-10, IL-13, and thymic stromal lymphopoietin (TSLP), thereby suppressing Th1 differentiation, inhibiting IFN-γ–driven neurotoxicity, and reshaping immune–glial crosstalk. Alleamit’s patented hyperallergenic platform provides a mechanistically grounded method for inducing sustained Th2 polarization while artificial intelligence–assisted immune monitoring can enhance safety, personalization, and therapeutic precision. Collectively, this framework supports immune reprogramming as a viable disease-modifying strategy in ALS and establishes a foundation for translational development.